IE 4: Week 13 Ethical Legal Reimbursement

studied byStudied by 0 people
0.0(0)
learn
LearnA personalized and smart learning plan
exam
Practice TestTake a test on your terms and definitions
spaced repetition
Spaced RepetitionScientifically backed study method
heart puzzle
Matching GameHow quick can you match all your cards?
flashcards
FlashcardsStudy terms and definitions

1 / 26

encourage image

There's no tags or description

Looks like no one added any tags here yet for you.

27 Terms

1

What are the types of genetic testing?

  • Direct-to-consumer genetic testing (DTC-GT)

  • Provider-mediated genetic testing (PM-GT)

    • Engages a healthcare professional (HCP) in a non-traditional role, i.e., HCP involvement might be limited to placing the test order or approving the order with minimal interaction/discussion with the consumer

  • Clinic-based genetic testing

    • Ordered, interpreted, and disclosed by an HCP through a traditional healthcare professional-patient relationship

New cards
2

Describe the types of genetic testing in terms of description, who orders it, and results?

  • Direct to consumer genetic testing → HCP not involved → consumer orders test → reported directly to consumer

  • Provider mediated genetic testing → consumer initiated with HCP involved → consumer or HCP orders test → reported directly to consumer with optional access to HCP

  • Clinic based genetic testing → facilitated by HCP → HCP orders test → results facilitated by HCP

New cards
3

In Direct to consumer testing, where are results sent to?

  • Sent to the consumers directly without clinician’s guidance

New cards
4

What are concerns in DTC Pgx testing?

  • Concerns of test validity and quality, misinterpretation of results, and the potential for inappropriate medical decisions

New cards
5

In 2013 FDA issued a warning to 23 and me to cease genetic tests for concerns about what? What happened in 2018?

  • 2013 FDA issued a warning letter to 23andMe, Inc., to cease marketing of genetic tests for concerns about disease susceptibility testing, pharmacogenomic testing and the potential for consumers to abandon therapy or self-manage dose adjustments based on results

  • FDA approved 23andMe’s Personal Genome Service Pharmacogenetic Report on October 31, 2018

    • Analytically and clinically valid

New cards
6

DTC PGx test result may not be used for what?

  • DTC PGx test result may not be used for clinical decision making unless FDA-approved

New cards
7

What are ethical issues (genetic discrimination) in PGx?

  • Overrepresentation of European ancenstry → generalizability is an issue, self reported vs continental ancestry in study enrollment, treatment guidelines of formulary

  • Genetic discrimination → set copay amounts for coverage, determine premiums

New cards
8

What are ethical implications in PGx testing?

  • Confidentiality - sharing genetic information

    • DTC tests

    • Highly sensitive information impacting beyond the patient

  • Data use - how the genetic data will be used and shared

    • Children

      • Who should receive the results? The child, his/her legal representative, his/her doctor

      • How and what should be reported?

    • Use by Government, law-enforcement

      • Current laws only protects against employers and health insurers


New cards
9

What are legal implications in PGx testing?

  • Health Insurance Portability and Accountability Act (HIPAA)

    • Specifies how protected health information is
      maintained and transmitted by covered entities

  • Genetic Information Nondiscrimination Act (GINA) - prohibits
    discrimination by health insurers and employers

  • How about discrimination by life insurers, lenders or other investors?

    • 2011 “CalGINA” (the California Genetic
      Information Nondiscrimination Act)- prohibits discrimination in housing and employment


New cards
10

What does medical insurance cover?

  • Covers outpatient clinic services

  • Covers office delivered prescriptions

  • Covers most inpatient costs

    • Services

    • Drugs

  • May cover vaccines (some or all)

  • Retroactive billing

  • PGx testing falls under Medical
    Insurance

New cards
11

What does pharmacy benefits cover?

  • Covers all outpatient drugs

  • May cover specific inpatient or clinic delivered medications

  • Do not cover inpatient drugs

  • Cover some vaccines

  • May cover MTM or other pharmacy cognitive services

  • Upfront adjudication

New cards
12

For medical benefit review of PGX, what is the focus on?

  • Focus is on:

    • Is PGX testing likely to reduce number of clinic visits?

    • Does PGX prevent potential serious adverse events?

    • Can successful treatment option be chosen without PGX?

    • How long will it take for the medical benefit to recoup the testing costs?

New cards
13

For pharmacy benefit review of PGX what is the focus on?

  • Focus is on:

    • Are the results of the test likely to result in the use of a non-preferred agent?

    • Will the test require that patient uses a high cost, brand-name only medication?

    • Do the results of the test require long-term use of a high-cost agent?

    • Are there alternative assessments to better evaluate appropriateness of a prescription drug?

New cards
14

Do all insurance companies cover PGx testing?

  • No

New cards
15

How has PGx testing historically been viewed as what?

  • PGx testing has historically been viewed as non-essential testing outside of oncology

    • You can prescribe a medication without PGx testing

    • If a safety or effectiveness issue arises, drugs can be switched

    • Many patients will receive proper medication without PGx testing

New cards
16

What Is a barrier in PGx testing?

  • Significant complexity in coverage as barrier

    • PGx testing is typically thought of as a lab test (medical benefit)

    • PGx testing primarily impact drug prescribed (prescription benefit)

New cards
17

For medicare and medical, how are test grouped? Which tests are covered?

  • Tests are grouped into Tiers

  • Tests which are Tier 1 are covered by Medicare and Medical (CMS)


New cards
18

Standard programs cover PGx testing under what?

  • The medical benefit

New cards
19

Coverage is limited to what based on evidence reviews? For example what does Aetna cover and not cover?

  • Coverage limited to certain drug-gene pairs based on evidence review

    • Aetna covers:

      • CYP2C19 for clopidogrel

      • Tumor biomarkers

    • Aetna Does NOT cover:

      • CYP2D6 for donepezil

      • CYP2D6 for beta blocker choice

      • Other P450 polymorphisms


New cards
20

What are barriers to PGx testing in a medical benefit?

  • Unless you implement, you can’t prove financial benefit. If you don’t have evidence of financial benefit, less likely to be implemented

  • Few utilization management strategies to encourage testing

    • Cost utility, cost benefit, cost effectiveness analysis

  • Testing is largely left to provider discretion

  • Medical benefits do not have strategies built to require testing before prescribing

  • Historically there have been few links between pharmacy and medical benefit

    • Makes it difficult to restrict reimbursement per drug

    • Require pre-authorization before running a test

    • Easier for insurers to restrict payment than encourage

      • Slows process

      • May result in limited use

New cards
21

For cost analysis of PGx testing, how are multiple budgets impacted?

  • Prescription drug costs impacts PBM budget

  • Cost of lab test impacts medical benefit budget

  • Theoretic savings typically impacts medical benefit budget

New cards
22

For cost analysis of PGx testing, return on investment requires company to what?

  • Be focused on total cost of care

  • Be able to link medical and pharmacy benefit

New cards
23

For implementing a PGx testing program, how it it currently managed?

  • Health system level

New cards
24

How should a system implement testing process to occur?

  • At diagnosis/assessment of need

  • Prior to a medication being prescribed

    • Need to ensure patient understands results of test and its implication

    • Ensure pharmacist is engaged in the process


New cards
25

What is the PA approach to implement pharmacogenomics testing?

  • 1.) Prescription is ordered

  • 2.) Patient tries to pick up prescription

  • 3.) PBM denies coverage and requires PA

  • 4.) PA informs prescriber that a pharmacogenomic test is required first

  • 5.) Pt sent pharmacogenomic test or returns to clinic

  • 6.) Test result come back

  • 7.) Results are reviewed by someone (who?)

  • 8.) Rx approved or denied based on results

New cards
26

The patient impact of PGx testing can result in what?

  • Increased lab costs (depending on if they pay for labs)

  • Increased out of pocket cost for medications

    • Plavix is available generically and comes with Tier 1 copayment /coinsurance

    • Effient is now available as generic prasugrel and comes with Tier 2 copayment/coinsurance

    • Brilinta is available brand name only, which typically require either PA or Tier 3 copayment/coinsurance

  • May cause patient delays in starting therapy

  • Places increased burden on the patient


New cards
27

What are barriers to implementing PGx?

  • Lack of sufficient knowledge of PGx

  • Minimal PGx training for healthcare providers other than pharmacists

  • Added cost of PGx testing (lack of insurance coverage)

  • Lack of actionable guidelines for drug selection and dosing using PGx

  • Lack of consistency in PGx testing and reporting

  • Lack of informatics infrastructure to integrate PGx data with other clinical data


New cards

Explore top notes

note Note
studied byStudied by 13 people
884 days ago
5.0(1)
note Note
studied byStudied by 37 people
869 days ago
5.0(1)
note Note
studied byStudied by 57 people
676 days ago
5.0(1)
note Note
studied byStudied by 82 people
388 days ago
5.0(2)
note Note
studied byStudied by 11 people
845 days ago
5.0(1)
note Note
studied byStudied by 7 people
915 days ago
5.0(1)
note Note
studied byStudied by 11 people
706 days ago
5.0(2)
note Note
studied byStudied by 337 people
211 days ago
5.0(1)

Explore top flashcards

flashcards Flashcard (50)
studied byStudied by 8 people
366 days ago
5.0(1)
flashcards Flashcard (78)
studied byStudied by 57 people
7 days ago
5.0(1)
flashcards Flashcard (87)
studied byStudied by 80 people
373 days ago
5.0(1)
flashcards Flashcard (30)
studied byStudied by 6 people
307 days ago
5.0(1)
flashcards Flashcard (20)
studied byStudied by 21 people
757 days ago
5.0(1)
flashcards Flashcard (25)
studied byStudied by 1 person
720 days ago
5.0(1)
flashcards Flashcard (96)
studied byStudied by 1 person
303 days ago
5.0(1)
flashcards Flashcard (68)
studied byStudied by 23 people
177 days ago
5.0(1)
robot